Impact of Q2 2026 Defense Spending on Moog's Margins and Market Outlook

Impact of Q1 2026 cancellations on Medpace’s project performance and outlook

1) What happened to cancellations in Q1 2026 (and why it matters)

• Medpace reported that “cancellations rise again” in Q1 2026, with “backlog cancels reaching their highest point in over a year.” ¹
• Management characterized the underlying drivers as “random stuff” such as product performance issues, re-prioritizations, etc., and explicitly stated it was not “particularly informed by acute financial shortages.” ²
• Management also noted that the largest therapeutic-area impact in the quarter was concentrated in oncology and cardiovascular. ²

Why this matters for project performance: when projects are cancelled after being counted in backlog (or delayed after being in pre-backlog), the work either stops or shifts in time, reducing the near-term set of projects that can convert into revenue. Medpace’s own commentary links higher cancellations to pressure on book-to-bill and taking away “from the total revenue opportunities in the year.” ²

---

2) Direct impact on Medpace’s execution metrics: net bookings, backlog, and book-to-bill

Even with elevated cancellations, Medpace still reported solid revenue and backlog figures in Q1:

• Q1 2026 revenue: $706.6 million (+26.5% YoY). ³
• Net new business awards entering backlog: $618.4 million (+23.7% YoY), producing a 0.88 net book-to-bill. ³
• Ending backlog (Mar. 31, 2026): ~$2.9 billion, up 2.9% YoY. ³
• Medpace projected ~$1.94 billion of backlog converts to revenue in the next 12 months, and Q1 backlog conversion was 23.3% of beginning backlog. ³

Connecting cancellations to performance: Elevated Q1 cancellations were described as pressuring book-to-bill in the period. ² The reported net book-to-bill of 0.88 (below 1.0) is consistent with an environment where cancellations reduce incremental revenue opportunities, even if new awards are still strong. ³²

---

3) Do cancellations signal a broader market funding problem?

Medpace management argued the answer is no:

• Cancellations were described as not driven by “acute financial shortages”. ²
• When asked whether heightened cancellations were attributable to past M&A, management responded no, stating cancellations in that bucket were not particularly elevated in Q1, and that M&A was not a driver. ⁴⁵

However, management also acknowledged a general truth: funding conditions can matter, but Medpace does not attempt to cleanly isolate it.

• Management said funding is “always one of the factors” in general, but it is hard to separate because of overlapping causes. ⁶

Bottom line for project performance: Q1 cancellations appear more execution- and sponsor-decision-driven (toxicity, product performance, re-prioritization, timing of study economics) than a systematic breakdown in Medpace’s demand base due to capital scarcity. ²⁷⁶

---

4) How cancellations relate to the kind of work being lost (in backlog vs pre-backlog)

Management’s discussion implies two different performance channels:

(a) Backlog cancellations (largest near-term revenue hit)

• Medpace said there was “backlog cancels” reaching a level highest in over a year. ¹
• They also stated cancellations were “just the kind of random stuff you’d expect… re-prioritizations” and higher than historically. ²
• They further said higher cancellations take away… total revenue opportunities in the year. ²

(b) Pre-backlog / pipeline opportunities (timing and future conversion risk)

• Management said Q1’s cancellation problems were more “backlog-related cancellations” and not specifically tied to pipeline size. ⁴
• They also explained that cancellations in earlier stages may be dominated by sponsor economics and program dynamics (for example, oncology discontinuation for toxicity, finishing early reducing study budgets, etc.). ⁷

---

5) Near-term outlook: guidance reconfirmed, but sequential growth is a concern

Despite the cancellation headwind, Medpace reconfirmed guidance, indicating that the current pipeline/backlog base is expected to support results within the stated range:

• Management stated they “reconfirm[ed] guidance” and felt “very good about the range that we have out there,” even with the Q1 cancellations headwind. ⁸

But management also warned that cancellations can impact guidance because they are near-term:

• Management added that future cancellations “could potentially impact” the guidance range, but right now they felt good about it. ⁸
• Separately, management stated their sequential revenue growth outlook is at risk: they said cancellations at a much higher rate (both backlog and pre-backlog) have resulted in “we don’t have revenue growth” sequentially, and that the growth profile now and 6 months from now is “a real question.” ⁹
• They characterized the situation as requiring either cancellations to abate or more gross awards/new notifications/bigger pipeline to offset the lost opportunities. ⁹

So the net effect on the future outlook is conditional:

• Guidance range is currently maintainable given the backlog conversion plan and reconfirmation. ³⁸
• Sequential performance beyond the immediate horizon depends on cancellations normalizing (or offsetting with stronger awards and pipeline conversion). ⁹²

---

6) What management says about durability: why revenue can hold even if cancellations are elevated

Medpace suggested that cancellations are less likely once substantial resources are invested and the work is “in backlog / in progress”:

• Management said that when it gets to the point where the quarter goes into backlog, they have expanded resources, and that is “highly unlikely to cancel.” ¹⁰
• They contrasted this with earlier-stage investment: “3 quarters before first patient in,” the investment/work is relatively small, and sponsors could cancel then. ¹⁰

This distinction helps explain why they can reconfirm revenue despite elevated cancellations:

• The reported backlog still had a conversion plan (e.g., $1.94B converting over 12 months, and 23.3% conversion in Q1) and they believed their model would keep them within guidance. ³¹¹

---

Overall conclusion

• Project performance impact (Q1 2026): Cancellations were higher than historically and backlog cancellations hit the highest level in over a year, concentrating in oncology and cardiovascular, and stemming from typical sponsor/program dynamics (product performance, re-prioritizations) rather than acute funding stress. ²¹
• Financial/operational impact: Cancellations pressured net book-to-bill (reported 0.88) even as Medpace delivered strong YoY revenue growth and a slightly higher backlog position. ³²
• Future outlook impact: Medpace reconfirmed guidance because the current backlog base and modeling still support results within the range. ⁸ At the same time, management emphasized that cancellations remaining elevated is a real risk to sequential revenue growth over the coming quarters, with the growth profile depending on cancellation abatement and/or stronger net awards and pipeline conversion. ⁹

If you want the impact summarized in one sentence: Q1 cancellations appear to be a near-term headwind mainly affecting backlog conversion timing (and book-to-bill), but Medpace currently believes guidance remains supportable—while sequential growth durability depends on whether cancellations normalize. ²⁹⁸